Cipla's shareholders 2024, by type

Published by A. Minhas, Aug 30, 2024

Promoters and Promoter Group held the majority of the share of about 33.4 percent in Cipla Limited during financial year 2024. The least shares were held by financial institutions and global depository receipts with 0.21 percent each in that year.

Shareholders of Cipla Limited in financial year 2024, by type

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

July 2024

Region

India

Survey time period

FY 2024

Supplementary notes

India's fiscal year starts in April and ends in March. For example, FY 2018 started in April 2017 and ended in March 2018

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Biotechnology industry in Europe "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Biotechnology industry in Europe

Overview

4

Research and Development

4

Financing and M&As

7

Patents

4

Countries

5

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical industry in ChinaCoronavirus COVID-19 in ChinaPharmaceutical industry in JapanVaccine industry in ChinaPharmaceuticals in India
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.